COVID-19 Clinical Trial
— HVaNaOfficial title:
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly
Verified date | March 2024 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Respiratory tract infections, e.g. caused by SARS-CoV-2, disproportionately affect elderly. Vaccination has shown to be the most cost-effective approach to prevent infections. However, older adults often fail to induce a potent immune response to vaccines, as was also seen recently for COVID-19 mRNA vaccines. This is likely due to immune dysfunction as a consequence of aging. To potentiate a stronger immune response, vaccine administration into the papillary dermis (intradermal, ID) has been proposed as an alternative strategy to intramuscular (IM) administration. Vaccination through the ID route has shown to be safe and equally or more effective than IM vaccination with a wide variety of vaccines. Recently, ID administration has been tested with two COVID-19 mRNA vaccines (Spikevax, Moderna and Comirnaty, Pfizer/BioNTech) in reduced (fractional) doses of the standard IM dose. To ease ID administration and thereby facilitate the implementation of this route, silicon-based microneedles have been developed. These needles have shown to allow ID administration of the Spikevax vaccine with equal safety and immunogenicity profiles as the traditional Mantoux approach in young adults. In the present study, we will investigate the immunogenicity of a 20 mcg dose of the COVID-19 mRNA Comirnaty vaccine through ID administration with silicon microneedles in elderly people (75 years and older), and compare this to immunogenicity of IM administration of a 20 mcg dose and a 30 mcg (standard IM) dose.
Status | Terminated |
Enrollment | 48 |
Est. completion date | March 21, 2024 |
Est. primary completion date | March 21, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 75 Years and older |
Eligibility | Inclusion Criteria: - Male or female aged =75 years at the moment of immunization. - Healthy, determined by medical history and clinical judgement of the investigator. Participants with a pre-existing illness that is stable, defined as disease not requiring significant change in therapy or hospitalisation during the 6 weeks before enrolment and not expected to require any intervention during the study, can be included. - Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures. - Willing to postpone their regular COVID-19 vaccination upon invitation by the Municipal Health Service or general practitioner until at least four months after receiving the intervention. - Completed a primary series of COVID-19 vaccination. - Capable and willing to give personal signed informed consent. - Adequate understanding of the procedures of the study and agrees to abide strictly thereby. - Fully conversant in the Dutch language. - Agrees his/her general practitioner is informed about participation in the study. - Agrees to provide access to information regarding their vaccination background. - Agrees that the study physician and his/her delegates have access to their medical file at Radboudumc. Exclusion Criteria: - Medical or psychiatric condition that may increase the risk of study participation or, in the investigator's judgement, make the participant inappropriate for the study. - No decision-making capacity. - History of severe adverse reaction to a vaccine or to any component of the study intervention. - Thrombose with thrombocytopenia syndrome after vaccination with a COVID-19 vaccine. - Dermatological conditions that might interfere with the ID vaccination. - Receipt of COVID-19 vaccination within 3 months before receiving the study intervention. - Known or suspected immunodeficiency, as determined by medical history or medication use (inhalation corticosteroids are allowed). - History of autoimmune disease or an active autoimmune disease requiring therapeutic intervention. - Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate IM injection. - Participation in other studies involving other study interventions within 28 days prior and during 28 days after receiving the study intervention. - Receipt of any other non-study vaccine within 28 days prior and after receiving the study intervention. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboudumc | Nijmegen |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Concentrations of SARS-CoV-2-Spike protein specific antibodies in serum and mucosal samples for the different intervention groups at various timepoints | Day 0, day 28 and month 4 after vaccination | ||
Other | Titers of SARS-CoV-2 specific neutralising antibodies in serum and mucosal samples of the different intervention groups at various timepoints | Day 0, day 28 and month 4 after vaccination | ||
Other | Changes in expression level of host genes | day 0 and day 1 after vaccination | ||
Other | Cellular responses in blood and mucosal samples at various timepoints | e.g. expressed as percentages of immune cell subsets or concentration of cytokines | Day 0, Day 28, month 4 after vaccination | |
Other | Functional and phenotypic characterization of T cells at various timepoints after vaccination | e.g. expressed as percentages of immune cell subsets or concentration of cytokines | Day 0, Day 28, month 4 after vaccination | |
Primary | Concentrations of SARS-CoV-2-Spike protein specific IgG antibodies in serum for the different intervention groups | at 28 days after vaccination | ||
Secondary | Titers of SARS-CoV-2 specific neutralising antibodies in serum of the different intervention groups | at 28 days after vaccination | ||
Secondary | The percentage of participants with local and systemic adverse events | Solicited adverse events (AEs): local reactions, reaction of regional lymph nodes, and systemic reactions up to 14 days following vaccination
Unsolicited AEs up to 28 days following vaccination Serious AEs (SAEs) up to 28 days following vaccination Use of antipyretics and analgesics up to 14 days following vaccination |
up to 28 days after vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|